Ductal variant prostate carcinoma is associated with a significantly shorter metastasis-free survival.
Chow K., Bedő J., Ryan A., Agarwal D., Bolton D., Chan Y., Dundee P., Frydenberg M., Furrer MA., Goad J., Gyomber D., Hanegbi U., Harewood L., King D., Lamb AD., Lawrentschuk N., Liodakis P., Moon D., Murphy DG., Peters JS., Ruljancich P., Verrill CL., Webb D., Wong L-M., Zargar H., Costello AJ., Papenfuss AT., Hovens CM., Corcoran NM.
BACKGROUND: Ductal adenocarcinoma is an uncommon prostate cancer variant. Previous studies suggest that ductal variant histology may be associated with worse clinical outcomes, but these are difficult to interpret. To address this, we performed an international, multi-institutional study to describe the characteristics of ductal adenocarcinoma, particularly focussing on the effect of presence of ductal variant cancer on metastasis-free survival. METHODS: Patients with ductal variant histology from two institutional databases who underwent radical prostatectomies were identified and compared with an independent acinar adenocarcinoma cohort. After propensity score matching, the effect of the presence of ductal adenocarcinoma on time to biochemical recurrence, initiation of salvage therapy and the development of metastatic disease was determined. Deep whole-exome sequencing was performed for selected cases (n = 8). RESULTS: A total of 202 ductal adenocarcinoma and 2037 acinar adenocarcinoma cases were analysed. Survival analysis after matching demonstrated that patients with ductal variant histology had shorter salvage-free survival (8.1 versus 22.0 months, p = 0.03) and metastasis-free survival (6.7 versus 78.6 months, p